Table 3.
Number of observed second tumours in a cohort of women with breast cancer in Turin (Italy), AJ-IR
| Cancer Site | Observed cases | AJ-IRstand (95% C.L.) |
| Mouth Pharynx | 7 | 0.80 (0.39–1.47) |
| Oesophagus | 5 | 2.38 (0.92–5.01) |
| Stomach | 29 | 1.38 (0.97–1.93) |
| Colon-Rectum | 66 | 0.87 (0.69–1.10) |
| Liver | 7 | 0.61 (0.23–1.30) |
| Gallbladder | 8 | 0.78 (0.38–1.40) |
| Pancreas | 20 | 1.39 (0.89–2.07) |
| Lung | 24 | 0.80 (0.54–1.15) |
| Melanoma | 14 | 1.15 (0.65–1.88) |
| Cervix uteri | 9 | 0.68 (0.34–1.22) |
| Corpus uteri | 54 | 1.91 (1.47–2.44) |
| Ovary | 24 | 1.12 (0.74–1.64) |
| Bladder | 14 | 0.74 (0.42–1.21) |
| Brain & NS | 4 | 0.56 (0.18–1.31) |
| Thyroid | 11 | 1.00 (0.46–1.89) |
| NHL | 21 | 1.32 (0.85–1.94) |
| Leukaemias | 9 | 0.81 (0.39–1.49) |
| Other & unspecified | 27 | 0.48 (0.33–0.68) |
| Total (breast and skin excluded) | 353 | 0.99 (0.91–1.10) |